A Preliminary Open-Label Study of Zonisamide Treatment for Bipolar Depression in 10 Patients
J Clin Psychiatry 2005;66(2):195-198
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The purpose of this study was to
investigate the effectiveness of zonisamide in the treatment of
Method: Ten patients with DSM-IV bipolar
disorder, depressed phase, who had either not tolerated or not
responded to previous treatments were given zonisamide in this
add-on open-label study. Zonisamide treatment was started at 100
mg/day and increased by 100 mg every 2 weeks to a maximum of 300
mg/day in divided doses (b.i.d. or t.i.d.). Subjects underwent
weekly visits at which they were administered the 17-item
Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating
Scale (YMRS), and Clinical Global Impressions scale (CGI). Every
2 weeks, subjects also underwent laboratory tests, a urine
examination, and a verbal memory test. Outcome measures were
analyzed with repeated-measures analysis of variance.
Results: Eight subjects completed all 8
weeks of the study. Two subjects completed more than 4 weeks of
the study, and their data were analyzed using the last
observation carried forward. Bipolar depression subjects had a
significant reduction in HAM-D scores (p < .001) and in
CGI-Improvement (CGI-I) scores (p < .001). Five of 8 subjects
who completed all 8 weeks of the study had more than a 50%
decrease in HAM-D scores and were rated much improved on the
CGI-I at the end of 8 weeks of treatment. There was no
significant drug effect on YMRS scores, weight, or verbal memory.
Conclusion: Zonisamide may be a useful
drug in the treatment of bipolar depression. Further controlled
clinical trials are needed.